Cardiff Oncology, Inc. Logo

Cardiff Oncology, Inc.

A clinical-stage biotech developing cancer therapies that inhibit Polo-like kinase 1.

CRDF | US

Overview

Corporate Details

ISIN(s):
US14147L1089
LEI:
Country:
United States of America
Address:
11055 FLINTKOTE AVENUE, 92121 SAN DIEGO

Description

Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel cancer therapies. The company's primary focus is on leveraging the inhibition of Polo-like kinase 1 (PLK1), a well-validated oncology drug target. Its lead drug candidate, onvansertib, is an oral PLK1 inhibitor being evaluated in clinical trials. These programs test onvansertib in combination with standard-of-care therapeutics for various cancer indications. The company's strategy is designed to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes for patients with significant unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-11-06 17:08
8-K
English ZIP 114.3 KB
2025-11-06 17:00
10-Q
English ZIP 1.0 MB
2025-08-28 18:56
S-8
English ZIP 460.8 KB
2025-08-14 19:06 English ZIP 10.1 KB
2025-07-31 18:05
4
English ZIP 6.7 KB
2025-07-29 18:10
8-K
English ZIP 29.4 MB
2025-07-29 18:00
10-Q
English ZIP 1010.8 KB
2025-07-29 13:26 English ZIP 8.3 KB
2025-07-08 18:05
3
English ZIP 6.0 KB
2025-06-30 11:39 English ZIP 6.9 KB
2025-06-30 11:38 English ZIP 7.0 KB
2025-06-30 11:38 English ZIP 6.9 KB
2025-06-27 22:45 English ZIP 5.2 KB
2025-06-27 21:40 English ZIP 4.2 KB
2025-06-27 21:38 English ZIP 6.9 KB

Automate Your Workflow. Get a real-time feed of all Cardiff Oncology, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cardiff Oncology, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cardiff Oncology, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Certara, Inc. Logo
Accelerates drug development using biosimulation software, technology, and services.
United States of America
CERT
CervoMed Inc. Logo
A clinical-stage biotech developing treatments for age-related neurologic disorders.
United States of America
CRVO
Chabiotech Co.,Ltd. Logo
Develops cell/gene therapies and provides CDMO and bio-banking services.
South Korea
085660
CHAMPIONS ONCOLOGY, INC. Logo
A CRO providing end-to-end solutions to accelerate oncology drug development.
United States of America
CSBR
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Logo
A contract research organization supporting drug discovery and development.
United States of America
CRL
Chiome Bioscience Inc. Logo
Clinical-stage biotech company developing antibody-based therapeutics.
Japan
4583
Chordate Medical Holding AB Logo
Develops a patented, drug-free neuromodulation treatment for migraine and rhinitis.
Sweden
CMH
Chordia Therapeutics,Inc Logo
Clinical-stage biotech developing novel cancer therapies targeting RNA deregulation.
Japan
190A
Cibus, Inc. Logo
Develops and licenses plant traits using non-GMO precision gene-editing technology.
United States of America
CBUS
Circio Holding ASA Logo
Clinical-stage company developing circular RNA medicines and immunotherapies.
Norway
CRNA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.